4519.T in “GLP-1 Eats Everything”
Chugai Pharmaceutical Co., Ltd.
Chugai originated and licensed the oral GLP-1 agonist orforglipron to Eli Lilly, giving it licensing economics tied to a potentially large oral-obesity market.
4519.T impact map — “GLP-1 Eats Everything”
How this story travels from the headline to 4519.T’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 4519.T impact map…
Price history, marked with story events
Jul 21, 2026 – Oct 19, 2026 · 60 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — Chugai originated and licensed the oral GLP-1 agonist orforglipron to Eli Lilly, giving it licensing economics tied to a potentially large oral-obesity market.
Read the full GLP-1 Eats Everything storyBull side
1 story- Viewing
4519.T in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Chugai originated and licensed the oral GLP-1 agonist orforglipron to Eli Lilly, giving it licensing economics tied to a potentially large oral-obesity market.
Bear side
1 story- America Imports the World's Drug Prices
4519.T in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Chugai’s portfolio of patented oncology, immunology and rare-disease medicines leaves its blockbuster economics exposed if U.S. reimbursement is benchmarked against lower developed-market prices.